Aims and Scope

Annals of Thoracic and Cardiovascular Surgery is an international, peer-reviewed, open access journal that publishes significant and novel contributions in thoracic surgery. The journal, which is supported by the Japanese Association for Coronary Artery Surgery, aims to facilitate the communication and progress of thoracic surgery worldwide.

Read more >

Welcome Essay from the Editor in Chief

Annals of Thoracic and Cardiovascular Surgery was first published in 1995 and is now in its 28th year of publication.

This journal is collated into issues six times a year and covers the fields of cardiovascular, respiratory, and esophageal surgery.

Read more >

Instructions to Authors

Annals of Thoracic and Cardiovascular Surgery supplies comprehensive and clear Instructions to Authors, which offer guidance on article types and format, journal policies, and how to submit manuscripts.

Read more >

The journal welcomes submissions from around the world.

Journal data

Online ISSN: 2186-1005
Print ISSN: 1341-1098
ISSN-L: 1341-1098

Online Journal


Turnaround times

Median submission to first decision: 15 days
Median acceptance to publication: 210 days

Citation indices

Impact Factor (2023): 1.1
Scimago Journal Ranking: 0.49(Q2)

SCImago Journal & Country Rank

Featured ArticlesView more articles >

Original ArticleJune 20, 2022

Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection Operations

Hassan, Kambiz; Bruening, Tabea; Caspary, Michael; Wohlmuth, Peter; Pioch, Holger; Schmoeckel, Michael; Geidel, Stephan

Objective: To analyze the results of hemoadsorption in patients with cardiac surgery to thoracic aortic surgery, who had been loaded beforehand with either Factor Xa inhibitor rivaroxaban or P2Y12 receptor antagonist ticagrelor. Methods: We investigated 21 of 171 consecutive patients (median age 71 [interquartile range 62, 76] years) who underwent emergency cardiac operations for acute type A aortic dissection between 2014 and 2020. These patients were pretreated with rivaroxaban (n = 9) or ticagrelor (n = 12). In ten of 21 cases (since 2017), we installed a hemoadsorber into the heart–lung machine and compared the results to eleven patients done without hemoadsorber before that time.

Read full Article >

Original ArticleApril 20, 2022

Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy

Liu, Zuo; Gao, Zhaoming; Zhang, Mengzhe; Wang, Xiaofei; Gong, Jialin; Jiang, Shuai; Zhang, Zhenfa

Purpose: Immune checkpoint inhibitors (ICIs) have been successfully used in many clinical trials related to immunotherapy. This study aimed to investigate the clinical efficacy of ICIs and prognostic factors in patients with resectable non-small cell lung cancer (NSCLC) following neoadjuvant therapy in the real world. Methods: A total of 170 consecutive patients were finally selected and divided into two groups: the preoperative chemotherapy group (n = 91) and the chemo-immunotherapy group (n = 79). The primary endpoint was disease-free survival (DFS). The secondary endpoints were pathological response, clinical response, pathological nodal disease, and ability of multivariate Cox regression analysis to predict survival. Survival was estimated using Kaplan–Meier method and compared using log-rank test.

Read full Article >

Case ReportApril 20, 2023

Salvage Robotic-Assisted Thoracoscopic Esophagectomy after Definitive Chemoradiotherapy for Clinical T4b Esophageal Cancer: A Case Report

Ryohei Sasamori, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Yushi Nagaki, Kazuhiro Imai, Yoshihiro Minamiya

The advantages of salvage esophagectomy through robotic-assisted surgery for patients with clinically diagnosed tumor invasion of adjacent vital organs (cT4b) or patients with scar tissue from definitive chemoradiotherapy (dCRT) are still only rarely reported. A man in his 60s with middle thoracic esophageal cancer (cT4b [left main bronchus] N1 M0 cStage IIIC) received dCRT (60 Gy). After the chemoradiotherapy, upper gastrointestinal endoscopy revealed a residual primary tumor, and we performed robotic-assisted thoracoscopic subtotal esophagectomy and gastric tube reconstruction via a retrosternal route with three-field lymphadenectomy.

Read full Article >

Original ArticleJune 20, 2022

Early and Mid-Term Outcomes of Open versus Endovascular Left Subclavian Artery Debranching for Thoracic Aortic Diseases

Philip Dueppers, Lorenz Meuli, Benedikt Reutersberg, Michael Hofmann, Florian Messmer, Alexander Zimmermann

Purpose: To compare open versus endovascular left subclavian artery debranching for thoracic endovascular aortic repair of thoracic aortic pathologies. Methods: This is a retrospective study of patients receiving left subclavian artery debranching in our institution from October 2009 to January 2020. The primary outcome was freedom from aortic reintervention. Secondary outcomes were type I endoleaks, left subclavian artery (LSA) debranching failure, stroke, technical or clinical success, procedure-related reintervention, as well as 30-day or overall all-cause and aorta-related mortality.

Read full Article >

About the Society

This journal is an associate journal of the Japanese Association for Coronary Artery Surgery.

The Japanese Society of Coronary Artery Surgery was established in 1996 and has a history of more than 20 years. It currently has about 800 members, making it one of the few societies in the world that specialize in coronary artery surgery.

This society contributes to the sustainable development of thoracic surgery by providing a platform for researchers in coronary surgery to disseminate their research results.

Contact details

Editorial Office
Annals of Thoracic and Cardiovascular Surgery
Email: atcs-edit[at] (Please replace [at] with @)